Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 17

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 17
---
? Stockholders who intend to have a proposal considered for inclusion in next year’s proxy materials for presentation at our 2026 annual meeting of stockholders pursuant 18

to Rule 14a-8 under the Exchange Act must submit the proposal in writing by December 22, 2025, to our Corporate Secretary at 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747. If you wish to submit a proposal (including a director nomination) for presentation at the Annual Meeting that is not to be included in next year’s proxy materials, you must do so by February 28, 2026, but no earlier than January 29, 2026; provided, however that if next year’s annual meeting is advanced more than 30 days prior to or delayed by more than 30 days after May 29, 2026, your proposal must be submitted (i) not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting; or if later, (ii) the tenth day following the day on which public announcement of the date of such meeting is first made. You are also advised to review our amended and restated bylaws (the “Bylaws”), which contain additional requirements about advance notice of stockholder proposals and director nominations.

In addition to satisfying the foregoing requirements under our Bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Board’s nominees must provide notice that sets forth the information required by Rule 14a-19(b) under the Exchange Act.

<div align='center'>19</div>

BACKGROUND OF THE SOLICITATION

Since at least February 2020, as part of the Company’s ongoing investor relations and stockholder engagement activities, the Company’s management has maintained regular dialogue with Mr. Mangless, including in the months leading up to our 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”), at which Mr. Mangless nominated three nominees for election as directors (Messrs. Bode, Calder, and Watton) and submitted a stockholder proposal. A detailed description of our communications with Mr. Mangless (through March 15, 2023) and other background information for our 2023 Annual Meeting was provided in our definitive proxy statement filed with the SEC on March 15, 2023 under “Background Of